Forty Seven nets $81mm in public offering
Oncology firm Forty Seven Inc. netted $81mm through a public offering of 10.78mm common shares (including the overallotment) at $8. Funds will support continued development of lead candidate 5F9, an anti-CD47 antibody in various clinical trials for solid and blood cancers. Earlier this month, Ono licensed exclusive rights to develop and sell 5F9 in Japan, South Korea, Taiwan, and the ASEAN countries.
- Large Molecule
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.